Inpatient hospital costs of febrile neutropenia as a consequence of chemotherapy for breast cancer and Non-Hodgkin lymphoma in Switzerland
Description
Febrile neutropenia (FN) can be a serious complication of chemotherapy (CHT), increasing mortality risk and healthcare costs. Incidence and inpatient hospital costs of FN in Switzerland are currently not reported. The study aims to: 1. Estimate the number of CHT induced FN-related hospitalizations. 2. Assess inpatient hospital costs per FN event in Switzerland.
Key data
Projectlead
Mark Pletscher, Dr. Renato Mattli
Project team
Prof. Dr. Simon Wieser, Prof. Dr. Klaus Eichler
Project partners
Amgen Switzerland AG
Project status
completed, 10/2012 - 12/2013
Institute/Centre
Winterthur Institute of Health Economics (WIG)
Funding partner
Third party